 |
The One Nine Three Group handled the IPO of JDE Peet's, the world's No. 1 pure-play coffee company based on revenues, which raised $2.5B in one of the biggest stock offerings of 2020.
The Wall Street Journal reported that the sale of a 14 percent stake in JDE Peet's is a bet by Netherlands-based parent company JAB Holdings on the resilience of coffee demand in spite of the COVID-19 pandemic, poor economic conditions and slumping IPO markets.
Olivier Goudet, JAB CEO, said JDE Peet's is well-positioned to be at the forefront of the IPO market, since its attractive growth prospects, business focus and commitment of the global team can help provide clear visibility for investors.
JDE Peet's brands include Douwe Egberts, Jacobs Coffee, Peet's Coffee, Kenco, Senseo and Tassimo, of which 80 percent of sales are for at-home consumption.
Launched with a valuation of $17.3B, JDE Peet's began trading May 29 on the Eurnext Amsterdam stock exchange. Shares closed up about 15 percent to $39.78
Zach Siegel, co-founder of New York-based One Nine Three with Matthew Freud, worked the JDE Peet's IPO.
He launched the One Nine Three in November after an eight-year run at Teneo and stints at Edelman and Cohn & Wolfe.
Interpublic posted a 5.1 percent drop in Q3 net revenues to $2.5B as CEO Philippe Krakowsky reports the final financial results of the publicly traded company.
Joele Frank handles Pine Gate Renewables as the Asheville, NC-based solar power development company declares Chapter 11 in the aftermath of Donald Trump’s cuts to wind & solar tax credits.
Stagwell CEO Mark Penn reports Q3 net revenues jumped 6 percent to $614.5M, a record performance for a non-political period. Operating income soared 45.7 percent to $60.9M.
Joele Frank works for Klöckner Pentaplast as the German maker of plastic films declares Chapter 11. A successful reorganization would slash its its corporate debt by $1.5B.
Teneo represents Metsera, the New York City biotech focused on weight-control products, which is subject to a bidding war between heavyweights Novo Nordisk and Pfizer.
